Clinical trial NCT06507254: Polyphenols and Cognitive Decline
Official title: MAEVE: Microbiota Mediated Flavonoid Metabolites for Cognitive Health
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Cognitive Decline
Cognitive Dysfunction
Keywords: Polyphenols
Mediterranean Diet
Gut Microbiome
Alzheimers Disease
Lead sponsor: University of California, Los Angeles
Sponsor class: OTHER
First posted: 2024-07-18
Enrollment: 300
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Globally, populations are aging thereby increasing healthcare burden, overall cognitive impairment, and dementia including Alzheimers diseases (AD). The lack of effective treatments makes it essential to develop new strategies for healthy cognitive aging, including interventions to slow or prevent cognitive decline. A traditional Mediterranean diet, rich in polyphenols (PPs), may prevent or delay the onset of cognitive dysfunction in older adults, preserving healthy brain structure and function, and lowering the risk of AD. These effects, mediated in part by gut microbiome-derived PP metabolites, highlight the role alterations in the brain-gut microbiome system play in neurodegeneration. Moreover, high levels of circulating phenyl-y-valerolactones, neuroprotective compounds, exclusively produced by gut microbiota from flavan-3-ol-rich foods (e.g., cocoa, tea, berries) are associated with delaying the onset of cognitive dysfunction in older adults. Intake of such PPs can also change gut microbial composition and function, altering the physiology of the hosts secondary bile acid (BA) pool, affecting regulatory and signaling functions in the brain as well as cognitive decline and AD. The investigators hypothesize that, in older adults with enhanced AD risk, dietary intake of PPs maintains healthier brain features and cognitive function, and that this beneficial effect is mediated by gut microbiota metabolites of PPs and BAs.

In this multi-PI application by leaders in the field of brain-gut microbiome interactions, the investigators will conduct a year-long, multi-center, randomized double-blind placebo-controlled study in 300 older adults in the United States (validation sample of 100 from Northern Ireland) who are at enhanced risk of developing AD. Ultimately, the investigators will establish the protective effects of regular dietary PP intake on cognitive function and on brain-gut microbiome interactions, ideally allowing the development of effective dietary regimes to prevent of delay the onset of AD in at-risk elderly, thereby reducing cognitive decline and healthcare costs.

Participants will be asked to provide information about their diet, mood, and behaviors via food diaries, physical body measures (e.g. height, weight, etc.), and online questionnaires collected before each in-clinic appointment, as well as monthly online questionnaires. MR imaging will be collected on participants to assess neurocognitive changes as a result of the supplement. Participants will be asked to provide both stool and blood samples. Participants will be randomly assigned to either the Juice Plus+ intervention group or the placebo treatment group and then asked to take their respective supplement 4 pills twice a day. All participants will be asked to come in for 4 in-clinic appointments, including 3 brain MRI scans and 3 cognitive testing appointments, collect 3 stool samples with corresponding diet diaries, and provide 3 blood samples over the course of 12 months. Participants will also meet with a nutritionist 3 times over the 12 months to discuss diet to ensure study eligibility and any questions about the supplement.


Eligibility criteria: Inclusion Criteria:

* 50+ Years of age
* Male or Female
* At enhanced risk of Alzheimers Disease (defined as family history of AD, 1st degree family member)
* Overweight or Obese (BMI≥25kg/m\^2)
* Habitually consume suboptimal diets such as typical Western Diet (i.e., high in animal products, refined carbohydrates and processed food)
* Able to communicate well in English

Exclusion Criteria:

* Vegan or Vegetarian
* Presence of cognitive impairment at the time of recruitment into the study as measured by the Mini Mental Status Exam (MMSE, score 25-30) and Clinical Dementia Rating (CDR, score=0).
* Pre-existing psychosis or psychiatric conditions
* Currently receiving treatment for dementia
* History of alcohol and/or substance abuse/dependence as determined by a positive endorsement on the MINI+/ If the MINI+ is positive for alcohol or drug dependence, or abuse, the participants will be excluded.
* Heavy use of tobacco (greater than 1/2 pack per day)
* History of cerebrovascular events
* Existing allergies to berry fruits
* Use of oral/IV antibiotics in the last 3 months. Use of probiotics in the last 1 month.
* Recent Changes (last 3 months) in the use of psychoactive medications or other medications that interfere with the measured outcomes.
* Frailty, malnutrition, or food allergy/intolerance requiring special diets.
* Body weight at enrollment greater than 400lbs due to weight restrictions on the MRI table.
* Women who are pregnant, lactating, or postpartum for less than 6months.
* Women of childbearing age who are not practicing birth control or are planning to get pregnant during the study.

Unable to safely participate in the MRI (claustrophobia, presence of devices affected by MRI such as pacemakers, neurostimulators, metallic foreign body, etc.)

* Chronic Pain

Primary outcomes:
measure: Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - stool
timeFrame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Polyphenol-derived metabolite concentrations pre, mid, & post intervention - blood
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in microbiome levels pre, mid, & post intervention - Stool
timeFrame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12).
measure: Differences in microbiome levels pre & post intervention - Blood
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in microbiome levels pre, mid, & post intervention - Stool
timeFrame: Collected three times by the participant at home, once at baseline (week 0), once at mid-study (month 6), and once at the final 12month appointment (month 12).
measure: Differences in microbiome levels pre, mid, & post intervention - Blood
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Cognitive Measures pre, mid, & post intervention - Executive Function
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Cognitive Measures pre, mid, & post intervention - Executive Function
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Cognitive Measures pre, mid, & post intervention
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Cognitive Measures pre, mid, and post intervention - Executive Functioning
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
Secondary outcomes:
measure: Differences in tryptophan-associated metabolite profiles pre, mid, and post intervention - Stool
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Bile Acid's (BA's) pre, mid, & post intervention - Stool
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Inflammatory markers pre, mid, & post intervention - Blood
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Differences in Alzheimer's Disease (AD) markers pre, mid, & post intervention - Blood
timeFrame: Collected three times, once at baseline appointment (week 0), once at mid-study appointment (month 6), and once at the final 12month appointment (month 12).
measure: Anthropometrics - BMI
timeFrame: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12)
measure: Questionnaire Data
timeFrame: Collected 3 times (1) before beginning the dietary supplement, (2) mid-study month 6, (3) end of study month 12.
measure: Monthly Questionnaire Data
timeFrame: Collected once a month for the duration of the study (12months).
measure: Anthropometrics - waist and hip circumference
timeFrame: Measured three times, once at each in-clinic appointment (week 0, month 6, & month 12)
measure: Systolic and Diastolic Blood Pressure
timeFrame: Measured three times, once at each in-clinic appointment (week 0, month 6, month 12).
Other outcomes:
measure: Differences in Multimodal Brain Signatures pre, mid, & post intervention
timeFrame: Measured thrice, once at baseline (week 0), mid-study (month 6), and final 12month appointment (month 12) visit.
Locations:
city: Los Angeles
country: United States
facility: University of California, Los Angeles
state: California
Study officials:
affiliation: The Regents of the University of California, Los Angeles
name: Arpana Church, PhD
role: PRINCIPAL_INVESTIGATOR
References: